ClinicalTrials.gg
Status unknownNCT03601871Updated Jul 26, 2018

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

An interventional study of Thalidomide and Dexamethasone in Chemotherapy-induced Nausea and Vomiting, sponsored by Yunpeng Liu. Status unknown at 29 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-26.

Sponsored by Yunpeng Liu · Not applicable, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Vomiting with a site in China — 22 open to participants now, 22 under way, 6 of them phase 3. Vomiting · China.

Planned enrollment
4th of 68
880 · median 150
Started
2018
with 3 others
No phase
22 of 73
6 open now
Registered
22nd of 73
by date

Among the 73 studies in Vomiting with a site in China, this one is the 4th largest by planned enrollment of the 68 interventional ones that give a count, is one of 4 that started in 2018, is one of 22 with no phase, and was the 22nd registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

Browse Vomiting studies →

Open to participants now

22 of the 73 studies in Vomiting with a site in China are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Vomiting with a site in China, or all of them as a file.
02

Study summary

This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle cisplatin-containing highly emetogenic chemotherapy (HEC) .

Read the detailed description

This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle cisplatin-containing highly emetogenic chemotherapy (HEC) . A total of 880 patients are planned to be enrolled into the study. Chemotherapy-naïve patients treated with multi-cycle cisplatin-containing chemotherapy will be randomized into two groups(thalidomide group and control group), and be treated with Thalidomide+5-hydroxytryptamine receptor(5-HT3) antagonist +Dexamethasone (Thalidomide group) or 5-HT3 antagonist + Dexamethasone(control group), respectively. The primary end point is no nausea rate in delayed phase of the first cycle chemotherapy, and the secondary end points include the complete response rate of vomiting in acute,delayed and overall period; no nausea rate in acute and overall phase; anorexia score, fatigue score and sedation score assessed by VAS ; safety and quality of life (QOL) during multi-cycle chemotherapy.

03

Conditions studied

  • Chemotherapy-induced Nausea and Vomiting

Browse trials for

Keywords

  • Thalidomide
  • Chemotherapy-induced Nausea and Vomiting
  • cisplatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18y ≤Age≤70y
  • (ECOG) Performance Status 0-2
  • confirmed solid neoplasm
  • No prior chemotherapy
  • Laboratory test must meet the following criteria: (HGB) ≥90g/ L, ≥1.5×109/L, count ≥85×109/L, rate (CCr) ≥60ml/min, total (TBil) ≤1.5 upper normal limitation (UNL), (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver , the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L
  • of at least 12 weeks
  • Signed
  • For women with child bearing potential, a negative serum or urine pregnancy test result should be obtained before enrollment;the patients and their couples should receive for at least 3 years after their last dosage of thalidomide.
  • Cancer patients scheduled to receive chemotherapy containing a 50 mg/m2 or higher dose of cisplatin for 4-6 cycles

Exclusion criteria

Exclusion Criteria:

  • Diabetic patients
  • Pregnant or lactated women
  • Patient with history of severe thrombosis
  • Concomitant radiotherapy
  • Known yo thalidomide, palonosetron, or dexamethasone.
  • Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs
  • Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or taxanes-based regiment
  • Existing emesis within 24 hours before chemotherapy administration
  • Symptomatic or suspected clinical brain metastasis
  • Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or other for therapy.
  • Inability to take or absorb oral medicine
  • Concurrent administration of any other drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment
  • Unsuitable for the study or other chemotherapy determined by investigator
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
880 participants (estimated)

Study arms

  • Active comparator
    Control group

    Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.

    Drug: Dexamethasone · Drug: 5-HT3 antagonists

  • Experimental
    Thalidomide group

    Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.

    Drug: Thalidomide · Drug: Dexamethasone · Drug: 5-HT3 antagonists

Interventions

  • Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .

  • Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4

  • Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3

    Also known as: Palonosetron, or 1st-generation 5-HT3 antagonists

06

What researchers measure

Primary outcomes

  1. No nausea (self report sclae VAS=0)rate in delayed phase (Days2-7) in the first cycle chemotherapy

    The rate of no nausea on Day 2-7 in the first chemotherapy cycle (each cycle is 21 days). The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).

    Time frame: Day 2-7 in the first chemotherapy cycle(each cycle is 21 days)

Secondary outcomes

  1. No nausea rates (VAS=0)for delayed phases (Days2-7) during 2nd to 4th or 6th chemotherapy cycle,respectively.

    The rates of no nausea on day 2-7 in 2nd-4th or 6th cycle (each cycle is 21 days). The no nausea is defined as score zero with a self-report measure scale,the visual analogue (VAS) scale (0,no symptom, 10, most severely).

    Time frame: Day 2-7 in each chemotherapy cycle (each cycle is 21 days)

  2. The complete response rates of vomiting (no emetic episode and no rescue) in acute (Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.

    The rates of no emetic episode and no rescue in acute(Day1),delayed(Day2-7), and overall phase(Day 1-7) during 1st to 4th or 6th cycle, respectively.(each cycle is 21 days). An emetic episode is defined as one occurrence of vomiting or a sequence of occurrences in close succession not relieved by a rest period of at least 1 min; any number of episodes of retching in a 5-minute period; or an episode of retching of , 5 minutes combined with vomiting not relieved in a 1-minute period.

    Time frame: Day 1-7 in 4-6 cycles(each cycle is 21 days)

  3. The rate of no anorexia (VAS=0) and score of anorexia (assessed by VAS) in Day1-7 during 1st-4th or 6th cycle chemotherapy

    The rate of no anorexia (VAS=0) and score of anorexia assessed by VAS in multi-cycle chemotherapy. Anorexia score is evaluated with VAS (0,no symptom, 10, most severely)

    Time frame: Day 1-7 in each cycle(each cycle is 21 days)

  4. The score of fatigue by VAS in day1-7 in1st to 4th or 6th chemotherapy cycle,respectively.

    The score of fatigue by self-report scale VAS in day1-7 in1st to 4th or 6th chemotherapy. fatigue is evaluated with self-report scale VAS (0,no symptom, 10, most severely)

    Time frame: Day 1-7 in each cycle(each cycle is 21 days)

  5. The score of sedation(by self-report VAS) in day 1-7 in each cycle

    The score of sedation(by self-report VAS) in day 1-7 in each cycle, respectively.Sedation is evaluated with self-report VAS (0,no symptom, 10, most severely)

    Time frame: Day 1-7 in each cycle(each cycle is 21 days)

  6. Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in multi-cycle chemotherapy

    Number of participants with Treatment-Related Adverse Events as assessed by CTCAE v4.0, in 4-6 cycles (each cycle is 21 days).

    Time frame: Day 1-21 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles (each cycle is 21 days)

  7. The quality of life scores (evaluated with Functional Living Index-Emesis (FLIE) questionnaire) of patients when receiving multi-cycle chemotherapy

    The change of quality of life scores from baseline of patients (before chemotherapy) to D8 after chemotherapy in each cycle (each cycle is 21 days). The quality of life are evaluated with Functional Living Index-Emesis (FLIE) questionnaire.

    Time frame: Day 1-8 in each cycle(each cycle is 21 days) during 4-6 chemotherapy cycles.

07

Study locations

2 of 29 sites recruiting
  • cancer hospital of Haerbin Medical University
    Haerbin, Heilongjiang, China
    Not yet recruiting
    • Jin Wu, M.D. · Contact
  • Siping City Cancer Hospital
    Siping, Jilin, China
    Not yet recruiting
    • Zhuohui Qu · Contact
    • Zhuohui Qu · Sub investigator
  • Anshan Hospital of First Hospital of China Medical University
    Anshan, Liaoning, China
    Not yet recruiting
    • Mingran Sun, PhD.M.D. · Contact
    • Mingran Sun · Sub investigator
  • Anshan Tumor Hospital
    Anshan, Liaoning, China
    Not yet recruiting
    • Xiuna Zhang, M.D. · Contact
    • Xiuna Zhang · Sub investigator
    • Jinfang Lv · Sub investigator
    • Fugang When · Sub investigator
    • Li Man · Sub investigator
  • Central hospital of Dalian
    Dalian, Liaoning, China
    Not yet recruiting
    • Wei Huo · Contact
    • Wei huo · Sub investigator
    • Min Zhong · Sub investigator
    • Liangwei Yin · Sub investigator
  • Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    Not yet recruiting
    • Zhaoxia Dai, M.D. · Contact
    • Zhaoxia Dai · Sub investigator
    • Jun Chen · Sub investigator
  • The Fifth Hospital of Dalian City
    Dalian, Liaoning, China
    Not yet recruiting
    • Jilai Bian · Contact
    • Jilai Bian · Sub investigator
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    Not yet recruiting
    • Jiwei Liu, PhD;M.D. · Contact
    • Jiwei Liu · Sub investigator
  • Zhuanghe Central Hospital
    Dalian, Liaoning, China
    Not yet recruiting
    • Huali Tang · Contact
    • Huali Tang · Sub investigator
  • Fushun Central Hospital
    Fushun, Liaoning, China
    Recruiting
    • Li Ning · Contact
    • Li Ning · Sub investigator
  • General Hospital of Mining Bureau
    Fushun, Liaoning, China
    Not yet recruiting
    • Yuyang Zhang · Contact
    • Yuyang Zhang · Sub investigator
  • Jinzhou Central Hospital
    Jinzhou, Liaoning, China
    Not yet recruiting
    • Wei Wang · Contact
    • Wei Wang · Principal investigator
  • The First Hospital of Liaoning Medical University
    Jinzhou, Liaoning, China
    Not yet recruiting
    • Zhitu Zhu · Contact
    • Zhitu Zhu · Sub investigator
  • Chinese Medicine Hospital of Liaoyang county
    Liaoyang, Liaoning, China
    Not yet recruiting
    • Haifeng Liu, M.D. · Contact
    • Haifeng Liu · Sub investigator
  • Liaoyang Central Hospital
    Liaoyang, Liaoning, China
    Not yet recruiting
    • Jian Zhang, M.D. · Contact
    • Jian Zhang · Sub investigator
  • Petrochemical General Hospital of Liaoyang city
    Liaoyang, Liaoning, China
    Not yet recruiting
    • Hao Chen · Contact
    • Hao Chen · Sub investigator
  • Panjin central Hospital
    Panjin, Liaoning, China
    Not yet recruiting
    • Junwei Zhang · Contact
    • Junwei Zhang · Sub investigator
    • Zhichang Sun · Sub investigator
    • Yu Jiang · Sub investigator
    • Qinghua Gao · Sub investigator
  • Chest Hospital of Shenyang City
    Shengyang, Liaoning, China
    Not yet recruiting
    • Yinyin Li · Contact
    • Yinyin Li · Sub investigator
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
    Not yet recruiting
    • Huawei Zou, M.D. · Contact
    • Huawei Zou · Sub investigator
    • Rong Wu · Sub investigator
  • General Hospital of Shenyang Military Region
    Shenyang, Liaoning, China
    Not yet recruiting
    • Zhendong Zheng · Sub investigator
  • Liaoning Tumor Hospital & Institute
    Shenyang, Liaoning, China
    Not yet recruiting
    • Yu Tang, M.D. · Contact
    • Yu Tang · Sub investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • Yunpeng Liu, M.D.;Ph.D. · Contact
    • Yunpeng Liu · Principal investigator
    • Xiujuan Qu · Sub investigator
    • Lingyun Zhang · Sub investigator
  • the People'S Hospital
    Shenyang, Liaoning, China
    Not yet recruiting
    • Lijie He, M.D. · Contact
    • Lijie He · Sub investigator
  • Tieling city Central Hospital
    Tieling, Liaoning, China
    Not yet recruiting
    • Huijun Zhang · Contact
    • Huijun Zhang · Sub investigator
  • Central Hospital of Anshan City
    Anshan, China
    Not yet recruiting
    • Chuanchun Leng · Contact
    • Chuanchun Leng · Sub investigator
  • Benxi Central Hospital
    Benxi, China
    Not yet recruiting
    • Tiejun Chen · Contact
    • Tiejun Chen · Sub investigator
  • Chaoyang Central Hospital
    Chaoyang, China
    Not yet recruiting
    • Xiujie Cui · Contact
    • Xiujie Cui · Sub investigator
  • Zhongshan Hospital
    Dalian, China
    Not yet recruiting
    • Xuening Ji, M.D. · Contact
    • Xuening Ji · Sub investigator
    • Gang Wang · Sub investigator
    • Tong Zhao · Sub investigator
  • Liaohe Oilfield General Hospital
    Panjin, China
    Not yet recruiting
    • Qiang Chen · Contact
    • Qiang Chen · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Jun 2020, 23 months after the start.

Of 132 non-industry interventional studies with no phase under Vomiting, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 29. This study's planned 23 months is above that.

Counting every sponsor, half of 135 studies reached it within 13 months; a quarter within 6 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2018
First posted
Jul 26, 2018
StartActual
Jul 12, 2018
Primary completionEst.
Jun 30, 2020
CompletionEst.
Dec 30, 2020
Last update
Jul 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03601871
Lead sponsor
Yunpeng Liu
Responsible party
Yunpeng Liu (Director of Department of Medical Oncology,The First Hospital of China Medical University, China Medical University, China) — Sponsor-investigator
First posted
Jul 26, 2018
Start date
Jul 12, 2018
Primary completion
Jun 30, 2020 (estimated)
Completion
Dec 30, 2020 (estimated)
Last update
Jul 26, 2018

Study contacts

Xiujuan Qu, PhD. M.D.
Contact
qu_xiujuan@hotmail.com
024-83282542
Lingyun Zhang, PhD. M.D.
Contact
zhangly1105@126.com
024-83282312
Yunpeng Liu, PhD. M.D.
principal investigator · China Medical University, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Thalidomide

Start the discussion